Protein clues may predict cervical cancer return

NCT ID NCT06147960

Recruiting now Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is looking at 180 women with advanced cervical cancer who were treated with radiation and chemotherapy. Researchers want to see if high levels of certain proteins (called IAPs) in the original tumor biopsy can predict whether the cancer will come back within two years. The goal is to find a way to identify patients who might need closer monitoring after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors identify which patients are at higher risk of their cervical cancer returning, allowing for more personalized follow-up care.
What could go wrong: This is an observational study, not a treatment trial. It only looks at protein levels in stored tumor samples, so it cannot prove that these proteins cause recurrence or lead to a new therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for APOPTOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer cervical carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

APOPTOSIS CANCER OF CERVIX

Contacts and locations

Locations

CHU de Nîmes
RECRUITING

Nîmes, Gard, 30029, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.